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Bulgecins as β-Lactam Enhancers 
Against Multidrug Resistant 
(MDR) Pseudomonas aeruginosa
Marion J. Skalweit
Abstract
Antibiotic resistance in non-lactose fermenting pathogens such as Pseudomonas 
aeruginosa (P. aeruginosa) is increasing, making these clinical pathogens more 
difficult to treat. Multiple resistance mechanisms exist within P. aeruginosa that 
affect all classes of antibiotics used in the clinic. New strategies and treatment 
targets within these MDR pathogens must be exploited. One heretofore untapped 
target is the family of cell wall enzymes known as lytic transglycosylases (Lts). Lts 
work in concert with penicillin binding proteins (PBPs) and other cell wall proteins 
such as amidases and peptidoglycan hydrolases to affect normal cell division, and 
during stress and programmed cell death. Lts are inhibited by natural products 
called bulgecins, produced by non-pathogenic Paraburkholderia and Burkholderia 
spp. New research describing the ability of Lt inhibition to restore susceptibility 
to β-lactams in MDR P. aeruginosa, as well as the structural biologic basis for the 
activity of bulgecins will be reviewed. Other targets and applications of bulgecins 
will also be discussed.
Keywords: antibiotic resistance, Pseudomonas aeruginosa, metallo-β-lactamase, 
penicillin binding protein, lytic transglycosylase, bulgecin A
1. Introduction
This chapter will review our current state of the art knowledge about bulgecins, 
natural inhibitors of lytic transgylcosylase cell wall enzymes, and their activity as 
β-lactam enhancers to inhibit growth of P. aeruginosa. Current known resistance 
mechanisms targeting β-lactams in P. aeruginosa be reviewed, followed by an 
introduction to the lytic transglycosylases of P. aeruginosa. The use of bulgecins 
as adjunctive agents with β-lactams will be described as well as the synthesis of 
Bulgecin A, the most active of these compounds.
2. β-Lactam resistance mechanisms in Pseudomonas aeruginosa
P. aeruginosa has intrinsically higher minimum inhibitory concentrations 
(MICs) against anti-pseudomonal β-lactams when compared to Enterobacteriaceae, 
even in the absence of specific resistance determinants. For example, typical 
MICs for the anti-pseudomonal cephalosporin, ceftazidime, for Escherichia coli 
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are 0.06–0.125 mg/L whereas for P. aeruginosa isolates, MICs are in the range of 
1–2 mg/L. In the main, when P. aeruginosa is resistant to β-lactams, specific mecha-
nisms are at play. These include downregulation of outer membrane porins, expres-
sion of intrinsic efflux mechanisms, acquisition of β-lactamase enzymes including 
carbapenamases such as IMP (“imipenemase”), VIM (“Verona imipenemase”) and 
KPC (“Klebsiella pneumoniae carbapenemase”), hyperproduction of chromosomal 
β-lactamases (“AmpCs or Pseudomonas-Derived Cephalosporinases, “PDCs”) and 
reduced penicillin binding protein affinity for β-lactams that are not considered 
“anti-pseudomonal” β-lactams. Table 1 summarizes the mechanism and resistance 
determinants responsible (adapted from [1]).
Currently, in the clinical microbiology laboratory, susceptibilities are reported 
to particular antibiotics depending on the specific sample submitted, e.g., urine, 
blood, sterile body fluids (pleural, joint, cerebrospinal fluid). At least initially, 
genotypic testing to determine the presence of specific antibiotic resistance deter-
minants is not performed, and it is left to the clinical infectious diseases expert to 
reason out the most likely resistance mechanisms based on susceptibility patterns, 
and to select the most appropriate antibiotic(s) for treatment.
2.1 Outer membrane porin loss (OprD)
The structure, function and regulation of P. aeruginosa porins is complex and has 
been recently reviewed [2]. Porins are involved in structural and signaling tasks in 
P. aeruginosa, as well as passage of nutrients. The Opr D family of porins is the largest 
and is subdivided into two groups OccD and OccK. These porins are each regulated 
through their own sigma factors. Porin loss can be related to formation of OprD con-
taining outer membrane vesicles that are also found in high concentrations in biofilms. 
Resistance to carbapenems in biofilms may be related to this. Mutations in P. aeruginosa 
that cause oprD (occD1) to not be expressed are linked to imipenem resistance. Other 
occD1 mutations that do not effect transcription also lead to carbapenem resistance 
[3, 4]. OprD mutations or loss is often associated with overexpression of efflux pumps 
(see below) leading to high level resistance to carbapenems, other β-lactams and other 
classes of antibiotics such as aminoglycosides and fluoroquinolones [5].
In the clinical setting, OprD porin loss is often associated with a resistance 
phenotype in which one observes resistance to carbapenems including imipenem, 
but in vitro susceptibility to anti-pseudomonal pencillins and cephalosporins. In 
Resistance determinant Antibiotics affected
Pseudomonas 
aeruginosa
OprD loss Carbapenems, some cephalosporins, penicillins
Efflux pumps (e.g., MexA-B/OprM) Meropenem, some cephalosporins, penicillins
Chromosomal Amp C of P. aeruginosa Anti P. aeruginosa penicillins, anti P. aeruginosa 
cephalosporins except ceftolozane
Acquired ESBLs (TEM, SHV,OXA, 
GES, VEB, CTX-M, PER)
anti P. aeruginosa cephalosporins except 
ceftolozane, cefepime
Acquired carbapenemases (KPC, 
OXA, metallo-β-lactamases like 
NDM, VIM, IMP, SPM types)
anti P. aeruginosa pencillins, cephalosporins 
and carbapenems
OprD, outer membrane porin D; Mex-multidrug efflux; TEM, class A β-lactamase of E. coli, named for patient 
in which it was discovered; SHV, sulfhydryl variant of TEM; OXA, oxacillinase; GES, German extended spectrum 
β-lactamase; VEB, Verona extended spectrum; CTX-M, cefotaximase-München; PER, plasmidic extended spectrum 
β-lactamase; NDM, New Delhi metallo-β-lactamase; SPM, Sao Paolo metallo-β-lactamase.
Table 1. 
β-Lactam resistance determinants in P. aeruginosa.
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combination with other resistance mechanisms, such as over-expression of the 
chromosomal PDC enzymes, or presence of other acquired cephalosporinases 
such as TEM, SHV and OXA β-lactamases, higher level carbapenem resistance is 
observed as well as resistance to other classes of β-lactam antibiotics.
2.2 Efflux pumps in P. aeruginosa
As with porins, P. aeruginosa possesses a large variety of efflux pumps that 
perform different roles in the bacteria, but mainly function to extrude harmful 
substances from the cell. These pumps have been reviewed in [6]. Pumps of impor-
tance in carbapenem and other antibiotic efflux are in the resistance nodulation or 
RND type family and include the MexAB-OprM, MexCD-OprJ, MexEF-OprN and 
MexXY-OprM multidrug efflux pump systems [7]. Increased expression of these 
pumps leads to high level carbapenem resistance, often in association with OprD 
loss or modification. Notably imipenem is not a substrate of the multidrug efflux 
pumps of P. aeruginosa while meropenem is [7]. In the clinical setting, if one notes 
resistance to meropenem and other β-lactams, except for imipenem, then an efflux 
mechanism is at play. If resistance is noted to both meropenem and imipenem, but 
not to other β-lactams, OprD loss or modification is responsible. With resistance to 
carbapenems as well as other β-lactams, multiple resistance mechanisms can be at 
play including efflux, intrinsic and acquired β-lactamases and decreased perme-
ability (porin loss).
2.3 Hyperproduction of PDC β-lactamases
As in other organisms, of which Enterobacter cloacae is the most well-known 
example, P. aeruginosa possesses a chromosomal AmpC β-lactamase also called 
PDC. Chromosomal β-lactamases likely play a role in cell wall maintenance, as 
well as degradation of β-lactam antibiotics. As characterized in E. cloacae [8], the 
AmpC cephalosporinases are under the regulation of ampR, a LysR type regulatory 
system [9]. Under normal circumstances, there is low level constitutive expression 
of the AmpC protein. Upon exposure to β-lactam antibiotics, muramyl penta-
peptides are released that displace a repressor protein encoded by ampR from the 
promoter of AmpC. This leads to increased expression of AmpC cephalosporinase. 
The increased expression of AmpC can occur with exposure to cephamycins like 
cefoxitin for example. Increased expression of AmpC in E. cloacae occurs via a 
pathway involving NagZ, a N-acetyl-β-D-glucosamindase, or independent of NagZ 
[8]. The muramyl pentapeptides are also degraded by a cytosolic amidase, Amp 
D. This leads to re-association of the repressor to the promoter and resumption of 
normal levels of Amp C expression. There are also insertion sequence mutations 
in AmpR that can lead to increased expression of AmpC, as well as mutations in 
AmpD amidases that reduce degradation of muramyl pentapeptides. The regula-
tion of Amp Cs differs somewhat in P. aeruginosa, involving 2 pathways that include 
the lytic transglycosylases Slt, SltB1, MltB and MltF, and PBP 4 in the generation 
of muramyl peptides [10]. Mutations in PBP4 are associated with higher levels of 
AmpC expression. Finally there are specific AmpC mutations that can lead to a 
carbapenemase phenotype in these enzymes, although the significance of this in 
terms of clinically relevant carbapenem resistance is unclear [11].
2.4 Acquired β-lactamases in P. aeruginosa
β-lactamases from all four Ambler classes have been described in P. aeruginosa, 
including Class A extended spectrum β-lactamases (ESBLs) of the TEM, SHV, 
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CTX-M, GES, PER and VEB types; Class A carbapenemases such as KPC variants; 
metallo-β-lactamases such as the VIM, IMP, NDM and SPM B1 di-Zn2+ enzymes: 
and OXA carbapenemases [9, 12]. Weak imipenemases in the so-called Class C 
AmpCs have already been discussed above. In combination with OprD loss and/or 
upregulation of MEX efflux pumps, high level carbapenem resistance can be seen in 
P. aeruginosa due to acquired β-lactamases. Traditional class A β-lactamase inhibi-
tors such as clavulanic acid, sulbactam and tazobactam have in vitro activity versus 
the Class A ESBLs but not against other β-lactamases, e.g., the anti-pseudomonal 
combination ceftolozane-tazobactam is not effective against KPC, metallo-b-
lactamases, or OXA enzymes [1]. New β-lactam-β-lactamase inhibitor combinations 
such as ceftazidime-avibactam and meropenem-vaborbactam will be active against 
isolates with KPC enzymes, and Class C β-lactamases, as long as they lack other 
resistance mechanisms that increase the β-lactam MIC beyond what is caused by the 
β-lactamase enzyme [13, 14].
2.5 Penicillin binding proteins (PBPs) of P. aeruginosa
PBPs of P. aeruginosa have high affinities for so called anti-pseudomonal 
β-lactams namely piperacillin, ticarcillin, ceftazidime, cefepime, ceftolozane, 
meropenem, imipenem, doripenem and aztreonam [1]. PBP 3 is the most important 
target of inhibition as it is essential for growth of the bacteria [15]. PBP3 is the pri-
mary target for ceftazidime whereas PBP2 is the target of carbapenems. Mutations 
in PBPs have not been described in P. aeruginosa leading to β-lactam resistance. The 
interactions of specific PBPs with specific lytic transglycosylases in the mainte-
nance of cell wall will be further discussed below.
2.6 Current therapeutic strategies to treat infections with resistant P. aeruginosa
Given that 15–33% of P. aeruginosa isolates are multidrug resistant (have at 
least one resistance mechanism) [16, 17] and that resistance is associated with up 
to fivefold greater mortality [18, 19], choosing the right antibiotic combinations 
have a tremendous impact on patient outcomes. Advances in the rapid diagnosis 
of P. aeruginosa, and use of both rapid phenotypic tests such as CARBA NP [20] or 
rapid molecular diagnostics to identify specific ESBL and carbapenemase enzymes, 
have enhanced the clinician’s ability to get patients on the right therapy sooner. 
Identification of patient risk factors, including prior antibiotic exposure, and 
knowledge of local trends in resistance patterns are useful in selection of empiric 
antibiotics, until antimicrobial susceptibilities and genotypic results are available 
for guidance. Carbapenems (meropenem or imipenem) and anti-pseudomonal 
cephalosporins in combination with colistin, an aminoglycoside or fosfomycin, 
versus ceftolozane/tazobactam or meropenem/vaborbactam or ceftazidime/avibac-
tam are all good empiric choices for critically ill patients [16], provided multidrug 
resistance is not present. However, clearly more therapeutic options are needed 
for infections with extensively drug resistant and pan-resistant P. aeruginosa. Lytic 
transglycosylases represent a new target for bacterial inhibition.
3. Lytic transglycosylases of P. aeruginosa
Recently, lytic transglycosylases of P. aeruginosa have been extensively character-
ized [21–27]. These cell wall proteins are found in many other pathogenic bacteria 
and are classified according to amino acid sequence and function [28]. To date there 
are 11 P. aeruginosa lytic transglycosylases that have been described. Their functions 
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range from cell division to aiding in the insertion of secretion systems and two com-
ponent regulatory systems. They are attractive drug targets to enhance the activity 
of our most commonly used and safest antibiotics, the β-lactam class (penicillins, 
cephalosporins, carbapenems and monobactams).
Lts in general catalyze a cleavage reaction that breaks the glycosidic bond 
between the peptidoglycan building blocks, MurNAc and GlcNAc (Figure 1).
This reaction does not involve a water molecule but rather, an active site Glu or 
Asp residue functions as a general acid, donating a proton to the oxygen in the β-1,4 
glycosidic linkage. Then the deprotonated active site residue acts a general base 
as a nucleophile to break the glycosidic bond. The result is a 1,6-anhydroMurNAc 
containing final peptide product. This unique cap on the muramyl peptide is a sig-
nal and a way for the cell wall peptidoglycan cleavage products to be trafficked for 
recycling [26]. The reaction shown in Figure 1 is within the strand or “endolytic”. 
Some Lts also catalyze an end of strand or “exolytic” cleavage.
Figure 1. 
Lt reaction in cell wall remodeling in Pseudomonas aeruginosa. When the transpeptidase (crosslinking 
function) of a PBP is inhibited by a β-lactam, the tranglycosylase function of the PBP continues to produce 
strands of uncrosslinked peptidoglycan (PG). The soluble Lt in the periplasm of Gram negative bacteria 
initiates recycling and cleavage of PG via endolytic (within strand) reaction. Once this first cleavage reaction 
occurs, the 1,6-anhydroMurNAC-GlcNAC containing fragments are cleaved and released. In P. aeruginosa, these 
1,6-anhydromuramylpeptide fragments affect regulation of Amp C β-lactamase production. TP designates tetrapeptide.
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Lts are classified according to amino acid motifs and function, into 6 distinct 
families. Even within a family, there is little sequence homology; however, the 
proteins in families do appear to share distinct folds (Figure 2). Lts are also divided 
into membrane (designated M in their nomenclature) and soluble (S) forms. It 
is hypothesized that these proteins are associated with numerous other cell wall 
proteins such as PBPs so that even the soluble Lts might be physically associated 
with the inner membrane of bacteria. Some Lts are also associated with the outer 
membrane, e.g., RlpA (see below) and likely have distinctive roles [29].
Lts serve many cellular functions including cell wall recycling, cellular division, 
insertion into cell wall of important structures like secretion systems and flagellar 
apparati. Lt redundancy is similar to that of the PBPs, and studies looking at gene 
knockouts of these proteins show that in P. aeruginosa, only loss of the RlpA LT is 
associated with a change in bacterial morphology [29]. Attempts to prepare multiple 
Lt knockouts were unsuccessful.
Recently significant research has been conducted on the Lts of P. aeruginosa, 
including structural and kinetic studies defining structure function relations in 
these varied proteins (reviewed in [26]). These studies are summarized next.
3.1 Kinetic studies of P. aeruginosa lytic transglycosylases
As previously indicated, P. aeruginosa possesses 11Lts: MltA, MltB/Slt35, MltD, 
MltF, MltF2, MltG, RlpA, Slt, SltB1 (SltB), SltB2 (SltG), and SltB3 (SltH).
In a tour-de-force of biochemical characterization, including synthesis, purifi-
cation and characterization of the reaction of soluble forms of all 11 P. aeruginosa 
Lts with 4 synthetic substrates and P. aeruginosa sacculus to yield 31 distinct pep-
tidoglycan (PG) products, Lee et al. [25] have thoroughly described the structure 
Figure 2. 
(A) Slt70 of E. coli in complex with Bulgecin A. (B) Lt of Neisseria meningitidis in complex with Bulgecin 
A. (C) Lt Cj0843 of Campylobacter jejuni in complex with Bulgecin A. (D) Slt inactive mutant E503Q from 
Pseudomonas aeruginosa in complex with Bulgecin A.
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function relationships for P. aeruginosa Lts. Of interest is that each solubilized Lt 
enzyme could perform both endolytic and exolytic reactions on the PG substrates.
Using the simplest synthetic substrate, NAG-NAM(pentapeptide)-NAG-
NAM(pentapeptide), Lee et al. found that only MltB and the SltB1–3 Lts could 
recognize this substrate. A second substrate, a NAG-NAM(tetrapeptide)-NAG-
anhydroNAM(tetrapeptide), incorporated the anhydroNAM that is likely 
recognized better by the exolytic Lts. For this substrate, MltA as well as MltB 
and the SltB1–3 Lts were able to react to convert 100% of the substrate to NAG-
anhdroNAMtetrapeptide product. The soluble Lts, SltB1–3 of P.  aeruginosa show the 
greatest activity in assays designed to study soluble proteins, as compared to solubi-
lized membrane Lts [25]. These Lts were able to cleave NAG-NAM(pentapeptide)-
NAG-NAM(pentapeptide) with specific activities of 0.4, 0.4 and 0.3 nanomoles of 
product/min/mg of protein respectively. Slt, the structural homolog of E. coli Slt70, 
showed no reaction with the synthetic peptidoglycan and slower turnover with the 
tetrapeptide substrate: 0.1 nmoles/min/mg.
3.2 Structural studies of the soluble Lts, Slt, SLtB1 and SltB3 of P. aeruginosa
X-ray crystal structures of Slt in its apo form as well as in complex with various 
synthetic PG substrates and reaction products demonstrated that this Lt has both 
exolytic and endolytic activity [23]. It is a donut shaped protein like Slt of E. coli. 
Notably, it is only after the binding of substrates that contain pentapeptide stems 
that it can exhibit endolytic activity due to a conformational change of the protein 
on substrate binding. A movie of this rearrangement is available in the supplemen-
tary material of reference [23]. Additional studies suggest protein–protein interac-
tions with inner membrane PBPs are also important [26].
SltB1 [22] and SltB3 [24] have also been studied using x-ray crystallography. SLtB1 
protein structures suggest that the protein forms a so-called “catenane” homodimeric 
structure in which the active sites face one another and are thus completely occluded. 
It is speculated that this soluble dimer may represent a form of activity regulation [22]. 
SltB3 is an exolytic enzyme with four distinct enzymatic domains within the donut 
shaped annular protein [24]. SltB3 can recognize PG substrates that are 4–20 sugars in 
length. These PG chains thread through the annular structure during catalysis.
3.3 Structural studies of the endolytic Lt, MltF
X-ray crystal structures of a solubilized MltF [21] show that this Lt binds a tetrapep-
tide stem of the substrate in an allosteric domain. Binding causes a large conformational 
change that leads to enzyme activation. In the kinetic studies, this solubilized mem-
brane had very low activity with any of the 4 synthetic substrates or the P. aeruginosa 
sacculus. This raises some questions regarding the actual role of this Lt and whether the 
conformational changes are relevant when the protein is membrane bound.
4. Bulgecins as Lt inhibitors
Bulgecins were first described by Imato et al. in the 1980s [30, 31]. These natural 
analogs of GlcNAC-MurNAC are produced by various bacterial species including 
Burkholderia mesoacidophila and Paraburkholderia acidophila [32, 33], part of the 
B. cepacia complex. Bulgecins are produced together with sulfazecin, a monobac-
tam antibiotic. Three different bulgecins are produced by these bacteria. Bulgecin A 
is produced in the highest amount and is the most active inhibitor of Lts (Figure 3, 
Bulgecin A).
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Early research by Takeda Pharmaceuticals Japan led to the natural product isola-
tion and purification of the bulgecins [30, 31]. It was discovered that when Bulgecin 
A was paired with a third generation cephalosporin, cefmenoxime, which targets 
PBP 3 of Enterobacteriaceae, large bulges were formed in the bacterial cell wall 
leading to osmotic lysis of the bacteria [30, 31]. Subsequently, investigators discov-
ered the soluble Lt of E. coli and solved crystal structures of SltE in complex with 
Bulgecin A [34]. Through kinetic experiments, it was determined that Bulgecin A 
was a noncompetitive inhibitor of SltE with an IC50 of 0.5 μM. [35]. While Bulgecin 
A appeared to be a potent inhibitor of Lts in pathogenic Enterobacteriaceae and led 
to bacterial killing when paired with β-lactams affecting PBP3 particularly, devel-
opment of the drug was halted for unknown reasons. Over the next decade, more 
advanced generation cephalosporins, as well as β-lactam-β-lactamase inhibitor 
combinations, carbapenems and fluoroquinolones were introduced into the clinic 
to address the growing problem of Gram negative resistance. Recently a natural 
product synthesis of the bulgecins was reported for the first time by Tomoshige 
et al. [36] prompting renewed interest in the use of Bulgecin A as an antimicrobial 
adjuvant, and possible drug optimization via medicinal chemistry.
Since the original discovery of the bulgecins and Slt in E coli, Lts have been 
characterized in many additional bacteria including P. aeruginosa, Acinetobacter 
baumannii, Helicobacter pylori, Neisseria meningitides and Campylobacter jejuni 
[21–25, 28, 34, 37–50]. In general, these organisms have many Lt enzymes with dif-
ferent functions, including endolytic (within strand) and exolytic (end of strand) 
cleavage of peptidoglycan. Many of these enzymes including those of P.  aeruginosa 
have been expressed for biochemical assays of function, and inhibition by Bulgecin A. 
Crystal structures of many of the Lts of these organisms have also been obtained, 
some with substrates or Bulgecin A in the active site (Figure 2).
A recent publication shows that while P. aeruginosa possesses 11 known Lts, 
three appear to be the main targets of inhibition by Bulgecin A [27]. This work is 
discussed further below.
5. Microbiological effects of Bulgecin A
Bulgecin A in combination with cefmenoxime and other β-lactams has been 
studied against Enterobacteriaceae and reported in the original studies by Takeda 
Pharamceuticals [30, 31]. Later investigators studied Bulgecin A in combination 
with ampicillin in mouse models of Helicobacter pylori infection and found that 
the combination was effective in eradicating the organism, and Bulgecin A did not 
Figure 3. 
Bulgecin A, the most active of the bulgecins of Paraburkholderia acidophila and Burkholderia mesoacidophila. 
The pyrrolidine ring (right side of the molecule) and the N-acetylglucosamine potion (GlcNAC) (left side other 
molecule) are features of Bulgecin A transition state structure.
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appear to have specific toxicity in mice [51]. These investigators also studied Bulgecin 
A with Neisseria gonorrhea and N. meningitides strains that were resistant to penicillin 
and amoxicillin [48]. For strains with higher penicillin MICs not due to the presence 
of TEM-1 β-lactamase, Bulgecin A at concentrations of 19 mg/L, reduced the MICs 
from 0.5 to 0.09 mg/L for penicillin G, and 0.75 to 0.4 mg/L for amoxicillin.
Other investigators examined the effect of Bulgecin A as a metallo-β-lactamase 
inhibitor using L1 MBL of Stenotrophomonas maltophila as a model B1 (di Zn2+) 
MBL enzyme (Figure 4). Simm et al. determined that the KI for Bulgecin A was 
150uM [52]. Later, our group investigated inhibition of VIM-1 using a Bulgecin A 
preparation from B. mesoacidophila and found that it also acted as an inhibitor of a 
second B1 MBL enzyme that is commonly found in P. aeruginosa in Europe, Asia and 
Canada, and rarely in the US [53].
Our group tested the Bulgecin A extracts from B. mesoacidophila against a vari-
ety of carbapenem resistant P. aeruginosa and Acinetobacter baumannii isolates with 
differing resistance mechanisms [53]. Although these were impure preparations, we 
found that small amounts were able to inhibit growth of these clinical isolates when 
combined with typical amounts of carbapenems to which the bacteria were other-
wise resistant. The Bulgecin A-meropenem combinations proved effective whether 
carbapenem resistance was due to the presence of MBLs (VIM-1), hyperproduction 
of PDC (Amp C enzyme of P. aeruginosa in combination with OMP loss) or efflux. 
Tomoshige et al. using synthetic Bulgecin A were able to demonstrate bulge forma-
tion in P. aeruginosa PA01 as well as lysis in the presence of ceftazidime [36].
6.  Slt, MltD and MltG are the main targets of Bulgecin A inhibition and 
potentiation of β-lactams that inhibit PBP2 and 3 in P. aeruginosa
Previously it was demonstrated that bulgecin A potentiated the bulge formation 
and lysis of P. aeruginosa in the presence of ceftazidime and meropenem [36] in a 
swarm assay [54]. Recently, Dik et al. [27] used individual transposon knockouts 
of. Lts in a susceptible P. aeruginosa strain, PA01 and further engineered a green 
fluorescent protein (GFP) gene into the bacteria. The various Lt knockout strains 
were exposed to ceftazidime, an inhibitor of PBP3 in P. aeruginosa and meropenem, 
an inhibitor of PBP2,3 and 4 [55] on agar medium containing propidium iodide. 
Bulge formation and bacterial cell lysis were monitored as a function of time by 
monitoring green fluorescence from viable cells, and red fluorescence during 
cell lysis, the red fluorescence arising from bacterial DNA interacting with the 
propidium iodide in the medium. In the presence of ceftazidime, the Slt and MltD 
knockouts formed bulges and showed lysis. The Slt knockout demonstrated signifi-
cant bulge formation within 6 hours of exposure to ceftazidime, and lysis within 
Figure 4. 
L1 MBL (left) of Stenotrophomonas maltophilia with Bulgecin A; Bulgecin A sulphonates (yellow moieties, 
right) interacting with the ZnII site and with Asp 14 of the L1 protein.
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9 hours. Some of the other knockouts demonstrated minor bulge formation (MltA, 
MltG, MltF, SltB1, SltB3) at 9 hours but none showed cell lysis. The effect was even 
more dramatic in terms of rapidity of bulge formation and cell lysis when merope-
nem was used. In fact, this semi-qualitative assay that involves spotting the bacteria 
and β-lactam at a given distance onto agar had to be modified for meropenem, as 
lysis occurred too quickly compared to conditions for ceftazidime. In the case of 
meropenem, an inhibitor of PBP2, Slt showed the greatest bulge formation and 
lysis, followed by MltG.
The soluble forms of five of the Lt enzymes were purified and bulgecin A 
binding constants measured: Slt Kd = 8.5 ± 1.1 μM; MltD Kd = 1.4 ± 0.3 μM; MltG 
Kd = 24 ± 5 μM, SltB1 Kd = 160 ± 20 μM; RlpA Kd = 1200 ± 280 μM.
Dik et al. [27] also demonstrated via scanning electron microscopy that 
cell wall failure within the bulge is responsible for cell lysis, in the presence 
of β-lactams and Bulgecin A. Withdrawal of the β-lactam antibiotic leads to 
delayed recovery of cell morphology in the presence of Bulgecin A alone, sug-
gesting further, the cooperative nature of the Lt and PBP functions in cell wall 
maintenance.
7.  Future prospects for antibiotic enhancers to treat P. aeruginosa 
infections
Now that the syntheses of the bulgecins A, B and C have been accomplished and 
purified Lt enzymes of many bacteria are available with simple commercial high 
throughput assays such as ENZCHEK lysozyme™ (substrate is a fluorescein labelled 
sacculus from Micrococcus lutei), it should not be long before potent derivatives of 
bulgecins are developed through medicinal chemistry approaches. Combinations of 
enhancers with novel β-lactamase inhibitor/potent anti-pseudomonal β-lactams are 
possibilities in the future antibiotic arsenal.
8. Conclusions
Antibiotic resistance in P. aeruginosa is on the rise in both inpatient and outpa-
tient settings. β-lactams remain among the most successful antibiotics due to their 
potency, efficacy and safety. Traditionally, β-lactamase inhibitors have proved 
able to extend the life of these valuable antibiotics. However, through a variety of 
resistance mechanisms, P. aeruginosa has eluded these approaches. Lts are novel 
cell wall enzymes that work in concert with PBPs to facilitate numerous cellular 
functions (insertion of secretion systems, cell division, etc.). When both Lts and 
PBPs are inhibited, bacteria exhibit abnormal bulging of cell wall and osmotic 
lysis. Bulgecins are naturally occurring compounds that inhibit Lts. Together 
with β-lactams, Bulgecin A can lead to effective bacterial killing, even when P. 
aeruginosa are resistant to the partner β-lactam antibiotics. Bulgecins are a novel 
β-lactam enhancer that may prove beneficial in the treatment of infections with 
resistant P. aeruginosa.
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